Inhibition of SKP2-Cyclin a Interaction
AssigneeAlbert Einstein College of Medicine of Yeshiva University
InventorsLiang Zhu, Peng Ji
Life of this patent
Estimating the term…
Abstract
Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell.
Claims19
A method of killing a cancer cell, the method comprising contacting the cell with a compound that inhibits binding of Skp2 with cyclin A in the cell.
A method of treating a subject having a cancer, the method comprising administering to the subject a compound that inhibits binding of Skp2 with cyclin A in an amount sufficient to treat cancer in the subject.
15-25. (canceled)
A compound comprising a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1.
27-34. (canceled)
A method of screening an agent for the ability to kill a cancer cell, the method comprising determining whether the agent inhibits Skp2—cyclin A binding, wherein an agent that inhibits Skp2—cyclin A binding could kill the cancer cell.
36-43. (canceled)
Dependencies are inferred from the claim text.